We have collaborations with world-class organizations and institutions at various stages of the R&D spectrum. Our clinical-stage partnerships focus on assessing optimal combinations of our drug candidates with other novel immuno-modulatory agents, as well as establishing the necessary safety and immunogenicity profiles of our clinical candidates. Our preclinical collaborations are aimed at generating supportive data to guide a potential future clinical path. We are also evaluating licensing opportunities with DPX-based therapeutic candidates in other hard-to-treat diseases.
An investigator-sponsored, Phase 2 clinical trial is evaluating our lead candidate, DPX-Survivac, with Merck’s checkpoint inhibitor, pembrolizumab, and low dose cyclophosphamide in patients with advanced ovarian cancer.
We are currently working with Dana-Farber Cancer Institute (DFCI) on a Phase 1b/2 clinical study evaluating our immuno-oncology candidate DPX-E7 in combination with low-dose cyclophosphamide in patients with incurable oropharyngeal, cervical and anal cancers related to the human papillomavirus (HPV). DFCI is leading the study through a $1.5 million research grant from Stand Up To Cancer and the Farrah Fawcett Foundation
Under this collaboration, IMV and The Wistar Institute partner to develop a targeted T cell therapy against the common BRAF cancer mutation, based on peptides identified by the Herlyn lab. Mutations in this gene are the most frequently identified cancer-causing mutations in melanoma and have been identified in various other cancers, including non-Hodgkin lymphoma, colorectal cancer, thyroid cancer, and non-small cell lung and ovarian carcinomas.The project scope includes optimizing the DPX formulation with the BRAF peptides and testing the investigational T cell therapy in the pioneering pre-clinical research models at Wistar. As part of the collaboration agreement, IMV holds an exclusive option to in-license intellectual property related to the program.
Our collaboration with UConn Health focuses on our DPX-NEO program. In preclinical studies, we demonstrated positive anti-cancer and immunogenic activity of patient-specific neoepitopes formulated in our DPX therapeutic T cell-activating platform We are currently evaluating future clinical paths for this exciting opportunity, considered by some researchers as ‘the next frontier’ in personalized cancer immunotherapies.
Our collaboration with Peregrine aims to determine the potential synergistic effects of combining our lead candidate DPX-Survivac with bavituximab, Peregrine’s investigational chimeric monoclonal antibody that targets phosphatidylserine (PS.) Preclinical research demonstrated that PS-targeting antibodies can enhance the anti-cancer activity of its DPX-based approach.
We have a multi-faceted collaboration with Leidos to explore potential applications of DPX-based approaches in some of the world’s most dangerous infectious diseases. Current preclinical research projects are evaluating potential uses in the Zika virus and malaria.
We established a collaboration with CIIE to assess the potential for DPX-based approaches to affect the most virulent form of malaria. Preclinical research demonstrated that CIIE-identified targets, when formulated in the DPX-targeting platform, generated strong, sustained, antibody responses that could prevent, after a single injection, the process of malaria that is most likely to result in death.
IMV has a long-standing partnership with Zoetis (formerly Pfizer Animal Health) to use the Company’s delivery technology to develop enhanced cattle vaccines.